Non-Prescription (OTC) / RECIGAR

RECIGAR

FILM-COATED TABLETS 1.5 mg

Smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. Using of medicinal product RECIGAR allows to gradually decrease nicotine dependence and disaccustom of tobacco smoking without nicotine withdrawal symptoms. The treatment goal of RECIGAR is the permanent cessation of the nicotine‑containing products use.

Posology
One package of RECIGAR (100 film-coated tablets) is sufficient for a complete treatment course. The duration of therapy is 25 days.

RECIGAR should be taken according to the following schedule:

Days of treatment Recommended dosing Maximum daily dose
From 1st  to 3rd  day 1 tablet every 2 hours 6 tablets
From 4th  to 12th  day 1 tablet every 2.5 hours 5 tablets
From 13th  to 16th  day 1 δισκίο κάθε 3 ώρες 4 tablets
From 17th  to 20th  day 1 tablet every 3 hours 3 tablets
From 21st  to 25th  day 1-2 tablets a day 2 tablets

Blister is labelled with the consecutive days of taking RECIGAR.

The person who smokes should stop smoke completely no later than on the 5th day of treatment. Smoking should not be continued during treatment as this may aggravate adverse reactions. The person who stopped smoking must not smoke even a single cigarette. In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months.

Special population (renal impairment, hepatic impairment)
There is no clinical experience of RECIGAR in patients with renal or hepatic impairment, therefore the drug product is not recommended for use in this patient population.

Elderly population
Due to limited clinical experience, RECIGAR is not recommended for use in elderly patients over 65 years of age.

Paediatric population
The safety and efficacy of RECIGAR in children under 18 years of age have not been established. RECIGAR is not recommended for use in children under 18 years of age.

Method of administration
RECIGAR should be taken orally with a suitable amount of water.

Terms of Use and Privacy Policy of the «RECIGAR» Mobile Application

Διαγραφή Λογαριασμού RECIGAR

Active substance: CYSTINE
Content: 1.5 mg
Form: FILM-COATED TABLETS
Package: BT x 100 tabs
Do not exceed the recommended daily dose
RECIGAR product packaging.